Status:
COMPLETED
Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Breast Neoplasms
Neoplasm Metastasis
Eligibility:
FEMALE
18-75 years
Brief Summary
The investigators want to develop a gene expression profile the for prediction the chemotherapeutic response of patients with metastatic breast cancer.
Detailed Description
1. Metastatic breast cancer tissue is obtained from core needle biopsies pretreatment and is flash frozen and stored at -70℃ until processing. 2. After patients received docetaxel combination thiotepa...
Eligibility Criteria
Inclusion
- Patients should be histologically confirmed with metastatic breast cancer;
- Patients who had completed the planned chemotherapy regimen with no major protocol violation;
- an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- At least one measurable lesion;
- Normal cardiac, hepatic, renal and bone marrow functions;
- Life expectancy ≥3 months;
- Discontinuity of previous chemotherapy for a minimum of 4 weeks.
Exclusion
- previous history of other malignancies;
- previous surgery history on the needle biopsy organ;
- Central nervous system metastases;
- Serious or uncontrolled concurrent medical illness.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01198301
Start Date
August 1 2010
End Date
July 1 2012
Last Update
July 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, China